Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)
Loomba, Rohit, Rinella, Mary, Harrison, Stephen, Wong, Vincent Wai-Sun, Ratziu, Vlad, Mohseni, Rizwana, Lucas, Kathryn Jean, Perry, Robert G., Rahmini, Robert, Trotter, James F., Gutierrez, Julio, GriVolume:
73
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(20)30653-X
Date:
August, 2020
File:
PDF, 62 KB
2020